P
PHARMAZZ INDIA PRIVATE LIMITED
Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Pharmazz is developing PMZ-2010 (centhaquin) as a resuscitative agent having a unique property of increasing blood pressure and cardiac output, and decreasing vascular resistance in hypovolemic shock. The company successfully completed human Phase I study of PMZ-2010 (NCT02408731; CTRI/2014/06/004647). A pre-IND meeting for phase II clinical studies was held with US FDA and Pharmazz is completing the required regulatory studies. Patents titled "Novel therapeutic treatments using centhaquin" have been issued: Australia Patent No. 2010241564; Japan Patent No. 5498571 and 5727642; China Patent No. 201080029672.5. In addition, the company is developing PMZ-1620 which is a neuroregenerative agent that produces neurogenesis and angiogenesis in the damaged area of the brain by stimulating endogenous regenerative mechanisms. US patent titled "Methods for treatment of stroke or cerebrovascular accidents using IRL-1620" US Patent No. 8,623,823 has been issued. China patent titled "Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin B receptor agonist" China patent No. ZL 2008 8 0113425.6 and European Patent Number EP2182977 have been issued. Potential indications of this product can be for the treatment of stroke, Alzheimer's disease, ALS, spinal cord injuries etc. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities.
Country/Area ：India
Company Email ：info@pharmazz.com
Industry ：Manufacturing GeneralManufacturing
Company address ：50 75th St Ste 105, Willowbrook, Illinois, 60527, United States
Company website ：*****
Company phone ：(630) 780-6087
Established ：2010
Company Revenue ：$7,206,000
Number of employees ：<25
SIC Code ：28283
NAICS Code ：32325
Company News
Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi, Sentien Biotechnologies, Basilea, Vivacelle Bio, Sanofi, BioAegis, Pharmazz
Jun 29, 2023
According to DelveInsight's’ estimates, the sepsis market in 7MM is expected to show good positive growth, during the forecast period (2023–2032), mainly attributed to the increasing prevalence of female predominance and elderly population. In addition, the launch of emerging therapies such as Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, and others by key companies will also propel the growth of the sepsis market in the coming years. According to DelveInsight's’ estimat
Jun 29, 2023
Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke PatientsMay 31, 2023
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002)
May 31, 2023Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke PatientsFeb 13, 2023
The primary endpoint is the proportion of patients with a good outcome as a modified Rankin Score (mRS) of 0-2 on day 90 post-randomization Sovateltide is an endothelin-B receptor agonist that has been shown to increase blood flow, inhibit apoptosis, and induce neurovascular remodeling...
Feb 13, 2023Clinical Phase III Trial Results Demonstrating Sovateltide's Efficacy to Treat Acute Cerebral Ischemic Stroke Presented at The International Stroke Conference 2023Feb 10, 2023
Sovateltide produced statistically significant and clinically meaningful improvements in neurological outcomes in acute cerebral ischemic stroke patients and was well tolerated The efficacy of sovateltide was similar in patients who received or did not receive thrombolytics WILLOWBROOK,...
Feb 10, 2023Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Agent in Hypovolemic Shock Patients at Upcoming Military Health System Research SymposiumSep 13, 2022
The study has shown the safety and efficacy of centhaquine as an adjuvant to standard of care (SOC) in the treatment of hypovolemic shock The study has shown the safety and efficacy of centhaquine as an adjuvant to standard of care (SOC) in the treatment of hypovolemic shock
Sep 13, 2022Business Info
CIN ：U24100DL2011FTC215954
Registered State ：Delhi
Registrar Of Companies ：RoC-Delhi
Category ：Company limited by Shares
Sub Category ：Subsidiary of Foreign Company
Company Class ：Private
Company Status ：Active
Registered Office Address ：FLAT NO.4, POCKET B, SARITA VIHAR NEW DELHI South Delhi DL IN 110076
Authorized Cap ：50000000.00
Paidup Capital ：38703905.50
Web Summary
Q1: Where is the headquarters of Pharmazz India Private Limited located?
A1: The headquarters of Pharmazz India Private Limited is located at H6, SiteC, Surajpur Industrial Area, Greater Noida UP 201307, INDIA.
Q2: What are some of the products developed by Pharmazz Inc.?
A2: Some of the products developed by Pharmazz Inc. include Lyfaquin (centhaquine) for hypovolemic shock, Sovateltide for cerebral ischemic stroke, and Centhaquine for acute spinal cord injury.
Q3: What is the focus of Pharmazz Inc.?
A3: The focus of Pharmazz Inc. is to discover, acquire, develop, and market novel pharmaceutical products for use in critical care and hospital settings.
Q4: Who is the CEO of Pharmazz India Private Limited?
A4: Dr. Anil Gulati is the Founder & Director, Chairman & CEO of Pharmazz India Private Limited.
Q5: What are some of the indications being targeted by Sovateltide?
A5: Sovateltide is being developed for acute spinal cord injury, cerebral ischemic stroke, and hypoxicischemic encephalopathy in neonates.
Q6: How did Pharmazz Inc. accomplish centhaquine development from bench to bedside?
A6: Pharmazz Inc. accomplished centhaquine development from bench to bedside in ten years.
Q7: What is the name of the firstinclass drug developed by Pharmazz India, a majorityowned subsidiary of Pharmazz Inc.?
A7: The firstinclass drug developed by Pharmazz India is Lyfaquin (centhaquine), which was approved for marketing authorization in India and launched in November 2020.
Q8: What is the name of the company's subsidiary based in India?
A8: The company's subsidiary based in India is Pharmazz India Private Limited, which is a majorityowned subsidiary of Pharmazz Inc.
A1: The headquarters of Pharmazz India Private Limited is located at H6, SiteC, Surajpur Industrial Area, Greater Noida UP 201307, INDIA.
Q2: What are some of the products developed by Pharmazz Inc.?
A2: Some of the products developed by Pharmazz Inc. include Lyfaquin (centhaquine) for hypovolemic shock, Sovateltide for cerebral ischemic stroke, and Centhaquine for acute spinal cord injury.
Q3: What is the focus of Pharmazz Inc.?
A3: The focus of Pharmazz Inc. is to discover, acquire, develop, and market novel pharmaceutical products for use in critical care and hospital settings.
Q4: Who is the CEO of Pharmazz India Private Limited?
A4: Dr. Anil Gulati is the Founder & Director, Chairman & CEO of Pharmazz India Private Limited.
Q5: What are some of the indications being targeted by Sovateltide?
A5: Sovateltide is being developed for acute spinal cord injury, cerebral ischemic stroke, and hypoxicischemic encephalopathy in neonates.
Q6: How did Pharmazz Inc. accomplish centhaquine development from bench to bedside?
A6: Pharmazz Inc. accomplished centhaquine development from bench to bedside in ten years.
Q7: What is the name of the firstinclass drug developed by Pharmazz India, a majorityowned subsidiary of Pharmazz Inc.?
A7: The firstinclass drug developed by Pharmazz India is Lyfaquin (centhaquine), which was approved for marketing authorization in India and launched in November 2020.
Q8: What is the name of the company's subsidiary based in India?
A8: The company's subsidiary based in India is Pharmazz India Private Limited, which is a majorityowned subsidiary of Pharmazz Inc.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
